By Wendy Sutherland-Smith_百度文库
两大类热门资源免费畅读
续费一年阅读会员，立省24元！
评价文档：
By Wendy Sutherland-Smith
H​i​d​i​n​g​ ​i​n​ ​t​h​e​ ​s​h​a​d​o​w​s​:​ ​r​i​s​k​s​ ​a​n​d​ ​d​i​l​e​m​m​a​s​ ​o​f
阅读已结束，如果下载本文需要使用
想免费下载本文？
你可能喜欢EXO D.O.与素珍再传恋爱说 “你是Wendy,比Cinderella还要美”
EXO成员D.O.与Girl's Day成员素珍正在恋爱中的传闻再度成为热门话题。
据悉，EXO成员D.O.与Girl's Day成员素珍正在恋爱中的传闻不只一次传出，但近日该传闻再次在网络论坛中成为热门话题。Like Us on
该传闻再度成为话题是因为Girl's Day的造型师在INS中的留言，该造型师近日在INS上传了一张素珍的后台认证照，并留言写道："素珍阿姨，你想飞吗？漂亮的素珍，像彼得潘的，精灵Wendy。是素珍让我写的，这是秘密！呵呵呵！"
随后，另一位与素珍亲近的粉丝留言表示："你是Wendy，比Cinderella还要美！"而这条留言刚好是EXO歌曲《彼得潘》中的D.O.Part的部分歌词。
其实，EXO成员D.O.与Girl's Day成员素珍的热恋传闻在粉丝们之间一直都受到了关注。二人不仅被粉丝们捕捉到一起佩戴情侣戒指、穿情侣鞋等照片，在网络上还流传了素珍和疑似D.O.的男子在一起钓鱼场约会的照片。
Girl's Day成员素珍也曾在Girl's Day大邱演唱会上表演《All Of Me》，而随后D.O.便表示《All Of Me》是他最喜欢的歌曲。
除此之外，从小学到大学都在大邱上学的Girl's Day成员素珍也曾透露她的初恋住在广津区，而不少粉丝们分析这与EXO的宿舍在广津区的相吻合，纷纷提出了素珍和D.O.正在热恋的疑惑。
请提供有效邮箱地址
7日SM表示雪莉将退出f(x)展开演技活动，之前雪莉在艺能节目中曾经表示泰妍和IU姐姐比自己更漂亮，再次吸引众多视线。
《我们结婚了》陆星材与Joy变身为大学情侣。
《魔女狩猎》徐仁英公开告白许智雄，吸引了大家的视线。
在李东健与智妍公开恋爱关系的话题势头正火的情况下，智妍关于初吻的发言再次吸引了人们的视线。
《Happy Together》李贤伊尽管丈夫也在摄影棚，但依然无法隐藏是玄彬的疯狂粉丝。
最受欢迎文章Studying wendy s menu ,i found that many of the items are similar to____of mcdonald s.A those B ones C any D all 答案是什么、然后为什么_作业帮
Studying wendy s menu ,i found that many of the items are similar to____of mcdonald s.A those B ones C any D all 答案是什么、然后为什么
Studying wendy s menu ,i found that many of the items are similar to____of mcdonald s.A those B ones C any D all 答案是什么、然后为什么
A.thoseitems 复数,所以用 those (那些)Wendy R. Sanhai, Ph.D., M.B.A. | LinkedIn
Wendy R. Sanhai, Ph.D., M.B.A., , Innovative Strategic Solutions, LLC, , 500+connectionsJoin LinkedIn & access Wendy R.’s full profileJoin LinkedIn and access Wendy R.’s full profile. It’s free!As a LinkedIn member, you’ll join 300 million other professionals who are sharing connections, ideas, and opportunities.See who you know in commonGet introducedContact Wendy R. directly500+connectionsMedicines for Malaria VentureMember of the BoardStarting November 2014
BackgroundAn effective healthcare executive with strategic and hands-on experience in the pharmaceutical and medical-device industries, the U.S. Federal Government, and academia. As the Senior Federal Officer and Chief Scientific Liaison on multiple scientific boards, I successfully navigated complex, sometimes contentious negotiations, and authored numerous scientific and business plans to facilitate the launch of multi-disciplinary programs in public health. I have a unique ability to identify areas of critical unmet public health and product development needs, and possess a track record of successfully creating, implementing, and managing large-scale, scientific initiatives that meet those needs. To lead international negotiations, with multiple partners, to develop innovative solutions for complicated healthcare problems, I am armed with strong training in the biomedical sciences, regulatory policy, an executive MBA, extensive business development experience, and many years of senior management experience. I am a skilled communicator with excellent interpersonal skills, well-honed business acumen, and extensive leadership experience in the development of regulatory strategies, and innovative research and development (R&D) programs, across numerous therapeutic areas and medical devices. Accomplishments include: successful execution and management of innovative, large, global studies in pediatric safety, nanomedicine, oncology, and cardiovascular disease. Expertise include significant leadership experience in creating, implementing, and managing strategic public-private partnerships for the development of innovative clinical trial designs, data registries, predictive tools, and assays that inform product design, development, and market launch, thereby reducing time and cost of product development. My success at identifying cutting-edge technologies, negotiating creative licensing deals, and managing joint ventures toward patient-focused product development is outstanding.ExperienceI develop innovative strategies and data-driven solutions for clients in regulatory affairs, R&D and healthcare practices to positively influence the healthcare and regulatory environments, toward the goals of efficient medical product development and patient benefit. My goals are to provide insights, options and innovative business models, that leveraging a range of expertise and resources toward meeting the needs of clients in the pharmaceutical, biotech and medical device industries.Innovative Strategic Solutions, LLC* Lead development and implementation of scientific and regulatory strategies and policies that influenced GSK's product development activities and the external regulatory environment.
* Staffed senior leadership on various Boards and Committees, making recommendations on efficient regulatory and R&D strategies on a variety of topics across multiple therapeutic areas.
* Developed and maintained critical links with government and trade associations (PhRMA and BIO) in the United States and advocated for adoption of key policies geared toward patient benefit.
* Provided interpretation, insights, and perspectives on possible impact on GSK of new U.S. legislation, regulatory guidelines, and policies to GSK leadership, to inform internal decision-making.
* Chief liaison with PhRMA and BIO on regulatory policies and advocacy activities that impact a broad spectrum of critical scientific, clinical and unmet public health needs.
* Lead the development and implementation of scientific and policy strategies across multiple therapeutic areas within GSK, and lead efforts to meet PDUFA goals.
* Developed extensive of training and awareness sessions for senior staff in Global Regulatory Affairs (GRA) and R&D, guiding various business units through complex business, scientific and regulatory strategies to facilitate product development, incorporating new requirements under the Food and Drug Administration Safety and Innovation Act (FDASIA).
* Implemented efficient processes for managing and leading GRA efforts across a spectrum of activities in GRA and R&D including, processes and policies for seeking and obtaining breakthrough designations from FDA, Special Medical U Biomarker developme and new paradigms for antibiotic drug development.
* Developed and managed dozens of internal and external teams working with external groups to ensure compliance with, an advocacy for, GSK’s regulatory and R&D policies and priorities.Led development, implementation and management of dozens of scientific initiatives and strategic programs and alliances under FDA's public health mission.
Developed novel clinical protocols and business models that bridged scientific gaps across various disciplines, and with partners from private industry, government and academia, creating aligned goals and missions, for mutual benefit.
Served as chief liaison on numerous scientific boards and scientific/regulatory committees.
Designed, negotiated, and implemented more than 100 public-private partnerships involving clinical- and translational-studies, producing know-how, best practices, predictive tools, and guidances to inform regulatory and R&D decisions toward more efficient medical product development and patient care.
Co-authored hundreds of articles, regulatory guidances, FR Notices and dozens of presentations on a variety of scientific, clinical and regualtory topics: nationally and internationally.
Preceptor in Commissioner's Fellowship Program.
HONORS & AWARDS:
Honor Award: For creating and publishing draft guidance and developing a process that describes an approach for review and qualification of Drug Development Tools (DDTs) intended for potential use in multiple drug development programs, 2011
FDA recognition Award: Outstanding contributions and leadership in developing and launching the Analgesic Clinical Trial innovations, Opportunities and Networks (ACTION) Initiative, 2011
Scientific Achievement Award: Outstanding Scientific Collaboration: SAFEKIDS Initiative, 2009
Scientific Achievement Award: Outstanding Scientific Collaboration: Dual Antiplatelet Therapy (DAPT) Trial Development, 2009
Office of the Commissioner, FDA: Leveraging/Collaboration Award, , 2009
Office of the Commissioner, FDA: Recognition Award: Tireless Commitment to the FDA’s Critical Path Initiative, 2006Responsible for creating, implementing and managing all new and existing programs in clinical research, education/training (including a number of NIH fellowship programs), that were priorities under NIH's mission. Served as chief liaison to FDA, and held membership positions on various clinical and scientific boards at NIH, industry and FDA.Managed a license and intellectual property portfolio of over 300 invention families, from across the 27 Institutes and Centers at NIH, academia and FDA. Successfully negotiated dozens of commercial licenses in multiple industry sectors that resulted in substantial royalties for NIH, and numerous product development options. Also conducted a full range of patent ending and business development activities in the public/private sector to promote research and development of new inventions.Clinical Fellow, Department of Pathology, University of Maryland, School of Medicine: (Shock Trauma, Operating Room, Emergency Department (ED), Neonatal (NICU) and Rapid Response Laboratories)
Faculty Member, Department of Medical and Research Technology (DMRT) University of Maryland, School of MedicineProjectsTeam members:, + Add team memberSkillsEducationMaster of Business Administration (M.B.A.), Strategy and NegotiationsClinical Fellowship, Department of Pathology, School of Medicine, Activities and Societies:&Member of Faculty, School of M Academic Researcher (cardiovascular disease); Clinical Fellow (Department of Pathology)Doctor of Philosophy (Ph.D.), Thesis: Structural Changes in Hepatocyte Keratins, Induced by Alcohol.Activities and Societies:&Lectured in biochemistry and medical histology: freshman classes for medical, dental and graduate students (class size: 250 students). Awarded &Excellence in Teaching& award from Medical School, 1999Bachelor's degree, Activities and Societies:&Lab Manager: Chemistry LaboratoriesA preview of what LinkedIn members have to say about Wendy R.:Pueblo a Pueblo (www.puebloapueblo.org)
Visiting Assistant ProfessorPublic Health Sciences
View Wendy R.’s full profile to...See who you know in commonGet introducedContact Wendy R. directlyNot the Wendy R. Sanhai, Ph.D., M.B.A. you’re looking for?
People Also ViewedClient Services Manager at Exponent (formerly Failure Analysis Associates)Area Partner Manager at Information BuildersAssociate Director, Regulatory Affairs at EthypharmSVP at PfizerCEO at Synchrogenix, a Certara companyPharmaceutical Project Manager at Department of Veterans AffairsTechnology Development AssistantMarket Development Specialist at BlackboardVisting Faculty at Symbiosis International University, School of Economics
LinkedIn member directory: